| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | LY-2183240 | CTRPv2 | pan-cancer | AAC | 0.0078 | 0.8 |
| mRNA | ruxolitinib | GDSC1000 | pan-cancer | AAC | 0.008 | 0.8 |
| mRNA | MK 1775 | CTRPv2 | pan-cancer | AAC | 0.0083 | 0.8 |
| mRNA | STF-31 | CTRPv2 | pan-cancer | AAC | 0.0086 | 0.8 |
| mRNA | NVP-231 | CTRPv2 | pan-cancer | AAC | 0.0079 | 0.8 |
| mRNA | BRD-K03911514 | CTRPv2 | pan-cancer | AAC | -0.013 | 0.8 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0081 | 0.8 |
| mRNA | elocalcitol | CTRPv2 | pan-cancer | AAC | 0.0082 | 0.8 |
| mRNA | Axitinib | CTRPv2 | pan-cancer | AAC | -0.008 | 0.8 |
| mRNA | Teniposide | CTRPv2 | pan-cancer | AAC | -0.0093 | 0.8 |